Physician profile
Donald Session
NPI 1518102243
$2,727.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $673 · 2022: $720 · 2023: $945 · 2024: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $681.25 | 2021-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $503.47 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.83 | 2021-2024 | Spiriva Respimat, Stiolto Respimat, Synjardy |
| Novo Nordisk INC | $322.85 | 2021-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $179.12 | 2022-2023 | |
| Pfizer INC. | $166.41 | 2023-2024 | |
| Exact Sciences Corporation | $134.28 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $110.94 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $92.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $50.10 | 2021 | |
| Mylan Specialty L.P. | $42.43 | 2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $16.82 | 2023 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $15.35 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.07 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Session listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.